Immix Biopharma, Inc. Common Stock (IMMX) is a publicly traded Healthcare sector company. As of May 21, 2026, IMMX trades at $9.49 with a market cap of $489.16M and a P/E ratio of -9.91. IMMX moved +1.02% today. Year to date, IMMX is +75.29%; over the trailing twelve months it is +323.70%. Its 52-week range spans $1.26 to $11.61. Analyst consensus is strong buy with an average price target of $18.25. Rallies surfaces IMMX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Immix Biopharma Achieves 95% CR Rate in 20-Patient NEXICART-2 Trial: Immix Biopharma's NEXICART-2 trial in relapsed/refractory AL Amyloidosis achieved a 95% complete response rate (19 of 20 patients), with all responses reached within one year post-dosing and no relapses observed. Subsequently enrolled patients are MRD-negative at one month, and a Phase 3 trial is slated following late September 2026 update.
| Metric | Value |
|---|---|
| Price | $9.49 |
| Market Cap | $489.16M |
| P/E Ratio | -9.91 |
| EPS | $-0.89 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.61 |
| 52-Week Low | $1.26 |
| Volume | 448.53K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-29.44M |
| Gross Margin | 0.00% |
4 analysts cover IMMX: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $18.25.